Adlai Nortye (ANL) Long-Term Investments (2024 - 2025)
Adlai Nortye (ANL) reported Long-Term Investments of $4.2 million for Q4 2025, up 2.21% year-over-year from $4.2 million in Q4 2024, and up 1.82% on a QoQ basis from $4.2 million in Q2 2025.
Adlai Nortye (ANL) has 2 years of Long-Term Investments data on file, last reported at $4.2 million in Q4 2025.
- Quarterly Long-Term Investments rose 2.21% year-over-year to $4.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.2 million (up 2.21% YoY) and the FY2025 annual result came in at $4.2 million, up 2.21% from the prior year.
- Long-Term Investments grew to $4.2 million in Q4 2025 per ANL's latest filing, from $4.2 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $4.2 million in Q4 2025 and bottomed at $4.2 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | 505,194.89 |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 5.75 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 9.79 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 22.17 Mn |
| 10 | Adlai Nortye | 23,840.00 | -8.03 Mn | - | 4.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.25 Mn |
| Jun 30, 2025 | 4.17 Mn |
| Dec 31, 2024 | 4.16 Mn |
| Jun 30, 2024 | 4.20 Mn |